Comparison of the pharmacological profiles of cyclosporine, (Nva2)-cyclosporine and (Val2)dihydro-cyclosporine.
The pharmacological profiles of two new derivatives of the immunosuppressive drug, cyclosporine, is presented here. (Nva2)-CS has very similar properties to CS, but lacks the nephrotoxic side-effects. This derivative appears to be a potential successor to cyclosporine. (Val2)DH-CS seems to have a different spectrum of activities. It does not suppress humoral immunity and allograft rejection, but suppresses some types of cell-mediated immune responses. This derivative may prove useful in autoimmune situations where T cells are involved in the disease process.
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D016572:Cyclosporine; D003524:Cyclosporins / Q000494:pharmacology* / Q000633:toxicity; D005260:Female; D006085:Graft Survival / Q000187:drug effects; D006087:Graft vs Host Reaction / Q000187:drug effects; D006168:Guinea Pigs; D006968:Hypersensitivity, Delayed / Q000517:prevention & control; D007075:Immunoglobulin M / Q000096:biosynthesis; D007166:Immunosuppressive Agents; D051379:Mice; D008815:Mice, Inbred Strains; D010081:Oxazolone / Q000276:immunology; D051381:Rats; D011919:Rats, Inbred Strains; D016038:Skin Transplantation; D014373:Tuberculin / Q000276:immunology
D003524:Cyclosporins; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; D014373:Tuberculin; D010081:Oxazolone; C041326:dihydrocyclosporin D; C045571:cyclosporin G; D016572:Cyclosporine